Subcutaneous beloranib: Interim Phase IIa data

Data from a pre-specified interim analysis of the first 19 obese patients who completed 12 weeks of treatment in a double-blind, Australian Phase IIa trial showed that twice-weekly 0.6, 1.2 and 2.4 mg subcutaneous beloranib each led to significantly greater mean weight loss from baseline to week 12 vs. placebo. Specifically, low-dose beloranib led to a mean weight loss of 3.8 kg, mid-dose beloranib led to a mean weight loss of 6.1 kg and high-dose beloranib led to a mean weight loss of 9.9 kg compared to a mean weight gain of 1.8 kg for placebo (p<0.005 for all). Zafgen also said that beloranib led to greater reductions from baseline to week 12 in LDL-C and C-reactive protein (CRP) levels vs. placebo, but that the small cohort was not powered for significance on these endpoints. ...